Project description
A novel platform for immunotherapy research and development
Despite its potential, immunotherapy against cancer has been met with limited clinical success. Therefore, there is a pressing need for alternative strategies to awaken the immune system against cancer customised for individual patients or according to tumour type. Towards this goal, scientists of the EU-funded LUMICKS project are developing z-Movi, the first high-throughput platform with a capacity to screen and sort immune cells based on their functionality. z-Movi will expedite the process of bringing new immunotherapy treatments to the market, therefore becoming an invaluable tool in the biopharmaceutical research and development pipeline.
Objective
Cell immunotherapy is a breakthrough treatment that uses immune cells to directly attack tumours. It is considered the most
exciting development in cancer treatment in years. When it works, patients with life-threatening cancers live far longer or
may even be cured. But so far, immunotherapy only works for few types of cancer and few patients, and finding the most
effective immune cells is still an immense challenge.
LUMICKS is developing z-Movi, the first high-throughput platform that screens and sorts immune cells based on their
functionality using non-invasive techniques. z-Movi is a unique and powerful solution that now allows researchers to look at
thousands of immune cells and find the right ones within a couple of minutes – a process that would take months with
standard technologies. Therefore, z-Movi is the perfect R&D tool to help and speed up the process of bringing new
immunotherapy treatments to market. z-Movi is expected to disrupt the immunotherapy market, which is mostly driven by
innovation and is expected to reach €100B by 2021.
LUMICKS started by teaming-up with immunotherapy leaders such as the Dutch Cancer Institute and Institut Pasteur to
develop z-Movi. The first developed z-Movi was already introduced to early adopters. After completing optimisation, a new
generation z-Movi will target the immunology research institutes, biotech and pharma markets. Users from those segments
have already demonstrated concrete interest in our solution, or are in the process of acquisition. The incremental z-Movi
revenue stream from this EIC Accelerator project will be around €20M by 2022 and the net profit margin will double.
LUMICKS’ post-EIC ultimate goal is to go beyond the
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1105 AG Amsterdam
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.